Sinead A Noonan1, Tejas Patil1, Dexiang Gao2, Gentry G King1, Jessica R Thibault1, Xian Lu3, Paul A Bunn1, Robert C Doebele1, W Thomas Purcell1, Anna E Barón3, D Ross Camidge4. 1. Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado. 2. Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado. 3. Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, Colorado. 4. Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado. Electronic address: ross.camidge@ucdenver.edu.
Abstract
INTRODUCTION: The role of serum tumor markers in the modern management of advanced NSCLC remains poorly described. METHODS: A single-center retrospective analysis of available carcinoembryonic antigen, CA125, CA19.9, and CA27.29 levels at baseline and during treatment of stage IV lung adenocarcinoma by oncogenic driver was conducted. RESULTS: A total of 142 patients were analyzed (60 with anaplastic lymphoma kinase gene [ALK] rearrangement, 50 with EGFR mutation, four with ROS1 rearrangement, and 29 with KRAS mutation). Of these, 82% had at least one marker (95% if all four markers were measured), with CA27.29 being the most commonly increased and CA19.9 the rarest. Only CA27.29 differed significantly by oncogene (it was less common in KRAS) (p = 0.016). The median times to nadir during tyrosine kinase inhibitor (TKI) therapy in EGFR and ALK cases were 16.4 and 20 weeks, respectively. Of the 41 patients with EGFR mutation or ALK or ROS1 rearrangement, 24 (59%) demonstrated an initial increase within the first 4 weeks of TKI therapy, 58% of whom then had their levels fall below baseline. An increase in marker level of 10% or more from nadir occurred in 53% of systemic and 22% of central nervous system-only progression. CONCLUSIONS: Serum tumor markers are frequently increased in lung adenocarcinoma regardless of driver oncogene. Changes within the first 4 weeks of therapy may be misleading. Progression is associated with marker increases, especially in sites other than the central nervous system.
INTRODUCTION: The role of serum tumor markers in the modern management of advanced NSCLC remains poorly described. METHODS: A single-center retrospective analysis of available carcinoembryonic antigen, CA125, CA19.9, and CA27.29 levels at baseline and during treatment of stage IV lung adenocarcinoma by oncogenic driver was conducted. RESULTS: A total of 142 patients were analyzed (60 with anaplastic lymphoma kinase gene [ALK] rearrangement, 50 with EGFR mutation, four with ROS1 rearrangement, and 29 with KRAS mutation). Of these, 82% had at least one marker (95% if all four markers were measured), with CA27.29 being the most commonly increased and CA19.9 the rarest. Only CA27.29 differed significantly by oncogene (it was less common in KRAS) (p = 0.016). The median times to nadir during tyrosine kinase inhibitor (TKI) therapy in EGFR and ALK cases were 16.4 and 20 weeks, respectively. Of the 41 patients with EGFR mutation or ALK or ROS1 rearrangement, 24 (59%) demonstrated an initial increase within the first 4 weeks of TKI therapy, 58% of whom then had their levels fall below baseline. An increase in marker level of 10% or more from nadir occurred in 53% of systemic and 22% of central nervous system-only progression. CONCLUSIONS: Serum tumor markers are frequently increased in lung adenocarcinoma regardless of driver oncogene. Changes within the first 4 weeks of therapy may be misleading. Progression is associated with marker increases, especially in sites other than the central nervous system.
Authors: Robert C Doebele; Xian Lu; Christopher Sumey; Delee A Maxson; Andrew J Weickhardt; Ana B Oton; Paul A Bunn; Anna E Barón; Wilbur A Franklin; Dara L Aisner; Marileila Varella-Garcia; D Ross Camidge Journal: Cancer Date: 2012-01-26 Impact factor: 6.860
Authors: Lyndsay Harris; Herbert Fritsche; Robert Mennel; Larry Norton; Peter Ravdin; Sheila Taube; Mark R Somerfield; Daniel F Hayes; Robert C Bast Journal: J Clin Oncol Date: 2007-10-22 Impact factor: 44.544
Authors: Andrew J Weickhardt; Benjamin Scheier; Joseph Malachy Burke; Gregory Gan; Xian Lu; Paul A Bunn; Dara L Aisner; Laurie E Gaspar; Brian D Kavanagh; Robert C Doebele; D Ross Camidge Journal: J Thorac Oncol Date: 2012-12 Impact factor: 15.609
Authors: Usha Menon; Andy Ryan; Jatinderpal Kalsi; Aleksandra Gentry-Maharaj; Anne Dawnay; Mariam Habib; Sophia Apostolidou; Naveena Singh; Elizabeth Benjamin; Matthew Burnell; Susan Davies; Aarti Sharma; Richard Gunu; Keith Godfrey; Alberto Lopes; David Oram; Jonathan Herod; Karin Williamson; Mourad W Seif; Howard Jenkins; Tim Mould; Robert Woolas; John B Murdoch; Stephen Dobbs; Nazar N Amso; Simon Leeson; Derek Cruickshank; Ian Scott; Lesley Fallowfield; Martin Widschwendter; Karina Reynolds; Alistair McGuire; Stuart Campbell; Mahesh Parmar; Steven J Skates; Ian Jacobs Journal: J Clin Oncol Date: 2015-05-11 Impact factor: 44.544
Authors: David Lang; Wolfgang Haslinger; Kaveh Akbari; Mario Scala; Benedikt Hergan; Christian Asel; Andreas Horner; Romana Wass; Elmar Brehm; Bernhard Kaiser; Bernd Lamprecht Journal: Lung Cancer (Auckl) Date: 2020-12-18